aTyr Pharma (NASDAQ:LIFE) Stock Crosses Above 200-Day Moving Average of $1.65

aTyr Pharma, Inc. (NASDAQ:LIFEGet Free Report)’s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.65 and traded as high as $1.95. aTyr Pharma shares last traded at $1.90, with a volume of 269,400 shares trading hands.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on LIFE shares. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of aTyr Pharma in a research report on Tuesday, May 14th. Royal Bank of Canada reduced their target price on aTyr Pharma from $19.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, March 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $23.67.

View Our Latest Stock Analysis on aTyr Pharma

aTyr Pharma Stock Performance

The firm has a market capitalization of $131.12 million, a PE ratio of -2.11 and a beta of 1.19. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.02. The business’s 50 day simple moving average is $1.76 and its two-hundred day simple moving average is $1.65.

aTyr Pharma (NASDAQ:LIFEGet Free Report) last posted its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.11 million. Research analysts expect that aTyr Pharma, Inc. will post -0.89 earnings per share for the current fiscal year.

Insider Buying and Selling

In other aTyr Pharma news, Director Timothy Coughlin bought 50,000 shares of the business’s stock in a transaction that occurred on Thursday, May 30th. The stock was bought at an average cost of $1.75 per share, for a total transaction of $87,500.00. Following the completion of the transaction, the director now owns 56,000 shares of the company’s stock, valued at approximately $98,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Sanjay Shukla acquired 20,000 shares of aTyr Pharma stock in a transaction dated Friday, May 31st. The stock was purchased at an average cost of $1.81 per share, for a total transaction of $36,200.00. Following the purchase, the chief executive officer now directly owns 136,548 shares of the company’s stock, valued at approximately $247,151.88. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Timothy Coughlin bought 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The stock was bought at an average cost of $1.75 per share, for a total transaction of $87,500.00. Following the completion of the acquisition, the director now owns 56,000 shares in the company, valued at approximately $98,000. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 75,000 shares of company stock valued at $132,650. 3.70% of the stock is owned by insiders.

Institutional Trading of aTyr Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC lifted its position in shares of aTyr Pharma by 119.6% during the 1st quarter. Acadian Asset Management LLC now owns 45,366 shares of the biotechnology company’s stock valued at $87,000 after buying an additional 24,704 shares in the last quarter. Vanguard Group Inc. lifted its holdings in aTyr Pharma by 12.0% during the first quarter. Vanguard Group Inc. now owns 2,652,157 shares of the biotechnology company’s stock valued at $5,172,000 after purchasing an additional 283,703 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of aTyr Pharma in the first quarter worth approximately $55,000. GSA Capital Partners LLP raised its position in shares of aTyr Pharma by 105.3% during the 1st quarter. GSA Capital Partners LLP now owns 224,147 shares of the biotechnology company’s stock valued at $437,000 after purchasing an additional 114,983 shares during the period. Finally, Kingswood Wealth Advisors LLC bought a new stake in shares of aTyr Pharma during the 1st quarter valued at $117,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

aTyr Pharma Company Profile

(Get Free Report)

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.

Read More

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.